SWOG clinical trial number
CTSU/A081801

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Open
Phase
Abbreviated Title
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Status Notes
Effective March 15, 2022, A081801 will be re-activated to accrual.
Activated
06/23/2020

Research committees

Lung Cancer

Treatment

Cisplatin Carboplatin Gemcitabine hydrochloride Radiation Therapy Pemetrexed MK-3475 Paclitaxel

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2021

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

J Sands;S Mandrekar;D Kozono;G Oxnard;S Hillman;D Wigle;R Govindan;J Carlisle;J Gray;J Salama;L Raez;A Ganti;N Foster;S Malik;J Bradley;K Kelly;S Ramalingam;T Stinchcombe Immunotherapy Jun;13(9):727-734. doi: 10.2217/imt-2021-0019. Epub 2021 Apr 21

PMid: PMID33878954 | PMC number: PMC8293026

Other Clinical Trials

SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open